Ann: Imugene Receives Second PD1-VAXX Ethics Trial Approval
IMUGENE RECEIVES SECOND ETHICS APPROVAL TO START PHASE I CLINICAL TRIAL OF NEW CANCER IMMUNOTHERAPY PD1-VAXX IN AUSTRALIA _______________________________________________________________________________________ • Macquarie University hospital receives human research ethics approval for Phase I human trial of anti-cancer immunotherapy PD1-Vaxx • Patient screening scheduled to commence in August • Ethics approval represents 2nd independent review of PD1-Vaxx pre- clinical safety and efficacy data SYDNEY, Australia, 17 July 2020:
And in case you missed it from a few weeks ago
Will 2020 be the start of immunotherapy dishing out a fatal blow to many forms of cancer? I hope so!
Positive results for pancreatic cancer but pushing ahead with testing in patients with Triple-Negative Breast Cancer (TNBC) which had equally positive pre-clinical data.